-transparent.png){kind=logo}
The use of a synthetic protease inhibitor, nafamstat mesilate, has enabled reliable estimations of in vivo complement activation to be made in patients with systemic sclerosis. Elevations of C3a and C4a anaphylatoxins were found in 2 and 24 out of 30 patients respectively, indicating that complement activation, predominantly by the classical pathway, is a common occurrence in the disease, even though complement C3 and C4 levels were within the reference range.
Related Publications
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
May 1987,
Lancet (London, England),
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
January 2013,
Arthritis research & therapy,
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
February 2022,
Journal of personalized medicine,
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
October 1989,
Arthritis and rheumatism,
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
January 1993,
Immunologic research,
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
November 1996,
Clinical and experimental dermatology,
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
June 2001,
Stroke,
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
January 1986,
Springer seminars in immunopathology,
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
April 1991,
Arthritis and rheumatism,
G Wild, and
J Watkins, and
A M Ward, and
P Hughes, and
A Hume, and
N R Rowell
August 1984,
The British journal of dermatology,
